Literature DB >> 11834964

Primary HIV-1 drug resistance in Abidjan (Côte d'Ivoire): a genotypic and phenotypic study.

Thomas d'Aquin Toni1, Bernard Masquelier, Dominique Bonard, Muriel Faure, Charlotte Huët, Anne Caumont, Pierre Roques, François Dabis, Roger Salamon, Hervé Fleury.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11834964     DOI： 10.1097/00002030-200202150-00024

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  7 in total

Review 1.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.

Authors:  Robert W Shafer; Soo-Yon Rhee; Deenan Pillay; Veronica Miller; Paul Sandstrom; Jonathan M Schapiro; Daniel R Kuritzkes; Diane Bennett
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

2.  Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.

Authors:  Marie-Laure Chaix; Didier Koumavi Ekouevi; Gilles Peytavin; François Rouet; Besigin Tonwe-Gold; Ida Viho; Laurence Bequet; Clarisse Amani-Bosse; Hervé Menan; Valériane Leroy; Christine Rouzioux; François Dabis
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

3.  Transmitted drug resistance in nonsubtype B HIV-1 infection.

Authors:  Philip A Chan; Rami Kantor
Journal:  HIV Ther       Date:  2009-09-01

4.  Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults.

Authors:  Eugène Messou; Delphine Gabillard; Raoul Moh; André Inwoley; Souleymane Sorho; Serge Eholié; François Rouet; Catherine Seyler; Christine Danel; Xavier Anglaret
Journal:  Bull World Health Organ       Date:  2008-06       Impact factor: 9.408

5.  R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.

Authors:  Bernard Masquelier; Cecile Droz; Martin Dary; Christian Perronne; Virginie Ferré; Bruno Spire; Diane Descamps; François Raffi; Françoise Brun-Vézinet; Geneviève Chêne
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

6.  Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.

Authors:  Catherine Seyler; Christiane Adjé-Touré; Eugène Messou; Nicole Dakoury-Dogbo; François Rouet; Delphine Gabillard; Monica Nolan; Siaka Toure; Xavier Anglaret
Journal:  AIDS       Date:  2007-05-31       Impact factor: 4.177

7.  Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.

Authors:  Rami Kantor; David A Katzenstein; Brad Efron; Ana Patricia Carvalho; Brian Wynhoven; Patricia Cane; John Clarke; Sunee Sirivichayakul; Marcelo A Soares; Joke Snoeck; Candice Pillay; Hagit Rudich; Rosangela Rodrigues; Africa Holguin; Koya Ariyoshi; Maria Belen Bouzas; Pedro Cahn; Wataru Sugiura; Vincent Soriano; Luis F Brigido; Zehava Grossman; Lynn Morris; Anne-Mieke Vandamme; Amilcar Tanuri; Praphan Phanuphak; Jonathan N Weber; Deenan Pillay; P Richard Harrigan; Ricardo Camacho; Jonathan M Schapiro; Robert W Shafer
Journal:  PLoS Med       Date:  2005-04-26       Impact factor: 11.069
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.